Evidence map›Paper›PMID 39412518›Full record

ArticleRheumatology (Oxford, England)2025

Unique transcriptomic profile of peripheral blood monocytes in rheumatoid arthritis-associated interstitial lung disease.

Jill A Poole, Aaron Schwab, Geoffrey M Thiele, Bryant R England, Amy J Nelson, Angela Gleason, Michael J Duryee, Kristina L Bailey, Debra J Romberger, Daniel Hershberger and 5 more

Abstract read
In one paragraph

Article in Rheumatology (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Jill A PooleDepartment of Internal Medicine, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Aaron SchwabDepartment of Internal Medicine, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Geoffrey M ThieleDepartment of Internal Medicine, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Bryant R EnglandDepartment of Internal Medicine, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.ORCID 0000-0002-9649-3588
Amy J NelsonDepartment of Internal Medicine, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Angela GleasonDepartment of Internal Medicine, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Michael J DuryeeDepartment of Internal Medicine, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Kristina L BaileyDepartment of Internal Medicine, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Debra J RombergerDepartment of Internal Medicine, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Daniel HershbergerDepartment of Internal Medicine, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Joel Van De GraaffDepartment of Internal Medicine, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Sara M MayDepartment of Internal Medicine, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Rhonda WalenzDepartment of Internal Medicine, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Bridget KramerDepartment of Internal Medicine, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Ted R MikulsDepartment of Internal Medicine, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.

Funding

UNMC Structural Biology CoreP20GM103427 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI PAUL L SORGEN · 2012 to 2026
$59.2M
UNMC/EPPLEY CANCER CENTER SUPPORT GRANTP30CA036727 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI James Eudy · 1985 to 2026
$55.0M
Tracking and Evaluation CoreU54GM115458 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI ZHANG, YING · 2016 to 2025
$42.8M
Pulmonary aging increases MUC5AC in the airway epithelium, increasing the risk of carcinogenesisI01BX006049 · VA · OMAHA VA MEDICAL CENTER · PI BAILEY, KRISTINA L · 2023 to 2025
–
Improving the Management of Rheumatoid Arthritis-Associated Lung Disease in Veterans Using Real-World DataIK2CX002203 · VA · OMAHA VA MEDICAL CENTER · PI Bryant R England · 2021 to 2026
–
BLRD VA I01 BX003635BLRD VA I01 BX004660BLRD VA I01 BX006049CSRD VA IK2 CX002203Department of Defence PR200793National Institute of Health 2U54GM115458National Institute of Occupational Safety and Health R01OH012045NCI NIH HHS P30 CA036727NIGMS NIH HHS P20 GM103427NIGMS NIH HHS U54 GM115458NIOSH CDC HHS R01 OH012045Rheumatology Research Foundation
6 · The paper itself

Abstract

objectivesThough interstitial lung disease (ILD) contributes to excess morbidity and mortality in rheumatoid arthritis (RA), RA-ILD pathogenesis remains incompletely defined. As intermediate, non-classical and suppressed CD14+ monocytes are expanded in RA-ILD, this study sought to characterize gene expression profiles of circulating monocytes in RA-ILD.

methodsPeripheral blood mononuclear cells were collected from patients with RA without lung disease (n = 5), RA-ILD (n = 5), idiopathic pulmonary fibrosis (IPF; n = 5), and controls without lung and autoimmune disease (n = 4). RNA was extracted from CD14+ isolated monocytes and subjected to transcriptional analysis of 1365 genes. Gene enrichment and pathway analyses were performed.

resultsUnsupervised clustering grouped patients with RA-ILD together with IPF for myeloid innate genes. For fibrosis genes, patients with RA-ILD clustered independent of comparator groups. There were 103, 66 and 64 upregulated and 66, 14 and 25 downregulated genes for RA-ILD, RA, and IPF, vs controls, respectively. For RA-ILD, there was increased expression of genes involved in regulating inflammation and fibrosis (SOCS3, CECAM1, LTB4R2, CLEC7A, IRF7, PHYKPL, GBP5, RAPGEF), epigenetic modification (KDM5D, KMT2D, OGT) and macrophage activation. Top canonical pathways included macrophage differentiation-activation, IL-12, neuroinflammatory, glucocorticoid receptor and IL-27 signalling.

conclusionsCirculating monocytes in RA-ILD patients demonstrate unique gene expression profiles, with innate immune gene features more aligned with IPF as opposed to RA in the absence of clinical lung disease, and with fibrosis gene expression that was distinct from RA and IPF. These studies are important for understanding disease pathogenesis and may provide information for future therapeutic targets in RA-ILD.

Indexed as

Arthritis, RheumatoidLung Diseases, InterstitialMonocytesTranscriptomeAgedCase-Control StudiesFemaleGene Expression ProfilingHumansIdiopathic Pulmonary FibrosisMaleMiddle Agedbloodcirculatinggeneinterstitial lung diseasemonocytepathwayrheumatoid arthritis

Identifiers

PMID39412518
PMCPMC12498283

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.